Obesity as a risk factor for Alzheimer's disease: weighing the evidence

Obesity Reviews - Tập 19 Số 2 - Trang 269-280 - 2018
Susan Alford1, Dhiren Patel2,3, Nikolaos Perakakis4, Christos S. Mantzoros5
1Novo Nordisk Inc., NJ, USA
2MCPHS University, Boston, MA, USA
3VA Boston Healthcare System, Boston, MA, USA.
4Mantzoros Lab, Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
5Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Tóm tắt

SummaryAlzheimer's disease (AD) is the sixth leading cause of death in the USA today; therefore, it is imperative that public health initiatives and clinical strategies are developed to prevent and effectively treat AD. Despite the enormous impact that AD has on individuals, families, society, and the health care system, there are no biomarkers to clearly identify those at risk for AD, public health prevention strategies in place, or treatments to address the underlying pathology or stop the progression of AD. There is ample scientific as well as empirical evidence that obesity and its metabolic and vascular comorbidities are related to AD and likely in the causative pathway. Obesity prevention and treatment could prove to be an efficacious and safe approach to preventing AD, a serious and daunting epidemic disease. In this review, we present the current pathophysiological and clinical evidence linking obesity and obesity‐related comorbidities (eg, insulin resistance, hyperglycaemia, and type 2 diabetes) with AD. Additionally, we discuss which population to target and when to consider treatment for AD. Finally, we summarize the current evidence regarding the efficacy of anti‐obesity and anti‐diabetic pharmacotherapeutic agents for the treatment of AD.

Từ khóa


Tài liệu tham khảo

10.1097/MCO.0b013e32831c8c71

Xu J, 2016, Deaths: final data for 2013, Natl Vital Stat Rep, 64, 1

Alzheimer's Association(2017).Prevention and risk of Alzheimer's and dementia. [WWW document].http://www.alz.org/research/science/alzheimers_prevention_and_risk.asp.

10.1016/j.jalz.2010.11.007

10.1016/j.bcp.2013.12.024

10.1016/S1474-4422(08)70143-1

10.1136/jnnp.2005.082867

10.1001/archneurol.2009.27

10.1001/jama.2017.3090

10.1001/archneur.62.10.1556

10.1186/alzrt104

10.1136/jnnp.2008.154146

Takashima A, 2009, Amyloid‐beta, tau, and dementia, J Alzheimers Dis, 17, 729, 10.3233/JAD-2009-1090

10.1111/j.1467-789X.2010.00825.x

10.1111/j.1467-789X.2008.00473.x

10.1038/mp.2015.129

10.1186/alzrt221

10.3233/JAD-130698

10.1212/01.wnl.0000306313.89165.ef

10.1146/annurev-immunol-031210-101322

10.1172/JCI57132

10.1179/147683008X301333

10.1037/a0017228

10.2337/db13-1954

10.1016/S1474-4422(14)70085-7

10.1186/s40035-016-0054-4

10.1007/s40263-013-0076-8

10.2337/db14-0568

10.1016/j.metabol.2014.10.016

10.1016/j.metabol.2014.07.004

10.1016/j.bbrc.2008.09.026

Perez‐Gonzalez R, 2011, Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse model of Alzheimer's disease, J Alzheimers Dis, 24, 17, 10.3233/JAD-2011-102070

10.1016/j.biopsych.2009.02.013

Droogsma E, 2015, The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study, Alzheimers Res Ther, 7, 18, 10.1186/s13195-015-0098-1

Elias MF, 2012, Obesity, cognitive functioning and dementia: back to the future, J Alzheimers Dis, 30, S113, 10.3233/JAD-2011-111175

10.2337/dc12-1017

10.1002/oby.20037

Gustafson DR, 2012, Adiposity and cognitive decline: underlying mechanisms, J Alzheimers Dis, 30, S97, 10.3233/JAD-2012-120487

Barrett‐Connor E, 1996, Weight loss precedes dementia in community‐dwelling older adults, J Nutr Health Aging, 44, 1147

10.1172/JCI59903

10.1001/archneurol.2010.225

10.1080/13803390903224928

10.1016/j.numecd.2005.07.011

10.3233/JAD-160891

10.1001/jamaneurol.2015.0613

10.2337/dc12-0922

10.1212/WNL.0b013e3181ffe4f6

10.1212/WNL.0b013e3181eee25f

10.1016/j.neurobiolaging.2009.12.005

10.1016/j.neurobiolaging.2013.03.025

10.1016/j.diabres.2016.10.024

10.3233/JAD-141521

10.1001/jamainternmed.2013.13656

10.1016/S1474-4422(11)70188-0

10.1212/WNL.0000000000003955

10.1016/j.metabol.2015.10.019

LaFerla FM, 2012, Animal models of Alzheimer disease, Cold Spring Harb Perspect Med, 2, 10.1101/cshperspect.a006320

10.2147/CIA.S74042

10.3233/JAD-2008-13309

10.1016/j.tem.2016.10.001

10.1038/ijo.2012.91

10.1002/jnr.22596

10.1111/j.1476-5381.2012.01971.x

10.1016/j.neuropharm.2014.07.015

10.1111/dom.12432

10.1111/cns.12404

10.1016/j.neuropharm.2013.04.008

10.1111/jphp.12148

10.1111/ejn.12088

10.1016/j.nbd.2011.12.043

10.1093/gerona/glu032

10.1016/j.brainresbull.2016.02.005

10.1111/j.1532-5415.2012.03916.x

10.2337/dc13-0229

10.1056/NEJMra041001

10.1016/j.cmet.2014.08.005

10.2165/00023210-200822010-00001

10.1016/j.ejphar.2010.05.030

10.1016/j.neulet.2013.10.052

10.1152/ajpcell.00317.2012

10.2174/18715273113126660160

10.1002/bab.1319

10.1016/j.neurobiolaging.2005.03.016

10.1212/01.WNL.0000265401.62434.36

10.1016/j.ejphar.2010.10.008

10.1001/archneurol.2011.233

10.3233/JAD-141791

University of Southern California.The Study of nasal insulin in the fight against forgetfulness (SNIFF)[WWW document].https://www.clinicaltrials.gov/ct2/show/NCT01767909.

Wake Forest University Health Sciences.Study of nasal insulin to fight forgetfulness – short‐acting insulin aspart (SNIFF‐Quick)[WWW document].https://www.clinicaltrials.gov/ct2/show/NCT02462161.

HealthPartners Institute.Intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease. [WWW document].https://www.clinicaltrials.gov/ct2/show/NCT02503501.

Beth Israel Deaconess Medical Center.Memory aid by intranasal insulin in diabetes (MemAID)[WWW document].https://www.clinicaltrials.gov/ct2/show/NCT02415556.

10.1152/physrev.00034.2006

10.1053/j.gastro.2007.03.054

10.1001/jama.2015.9676

10.1007/s40263-015-0301-8

10.1038/jcbfm.2012.133

10.1002/jnr.23335

10.1016/j.molmet.2015.07.008

10.1210/en.2014-1675

10.1007/s00125-016-3874-y

10.1016/j.bbr.2009.06.035

10.3389/fnagi.2016.00108

Imperial College London.Evaluating liraglutide in Alzheimer's disease (ELAD)[WWW document].https://clinicaltrials.gov/ct2/show/NCT01843075.

Azienda Ospedaliero‐Universitaria di Parma.Long‐acting exenatide and cognitive decline in dysglycemic patients (DRINN)[WWW document].https://www.clinicaltrials.gov/ct2/show/NCT02847403.

10.1111/1440-1681.12455

10.1016/j.diabres.2016.12.010

10.1111/j.1463-1326.2004.00448.x

10.1097/00019442-200511000-00005

10.1038/sj.tpj.6500369

10.1159/000318845

10.2174/156720511796391935

10.1001/archneurol.2010.229

10.2337/diabetes.51.2007.S368

10.1089/neu.2009.1021

10.1016/j.bbr.2017.06.038

10.1016/j.neuropharm.2015.09.030

10.3233/JAD-2011-101524

10.1111/jdi.12214

10.1038/oby.2012.19

Thông tin
Thông tin xuất bản

Obesity Reviews

Tập 19 Số 2

269-280

Thông tin tác giả